Mounjaro vs Ozempic vs Wegovy: 2026 Complete Comparison Guide

Mounjaro, Zepbound, Ozempic, and Wegovy are four brand names but only two distinct molecules. Mounjaro and Zepbound are both tirzepatide, an Eli Lilly compound. Ozempic and Wegovy are both semaglutide, a Novo Nordisk compound. The clinically meaningful comparison is therefore tirzepatide versus semaglutide, with the brand split simply reflecting whether the FDA indication is type 2 diabetes or chronic weight management.

• Mounjaro = tirzepatide for T2D (Eli Lilly, FDA 2022)
• Zepbound = tirzepatide for obesity (Eli Lilly, FDA 2023)
• Ozempic = semaglutide for T2D (Novo Nordisk, FDA 2017)
• Wegovy = semaglutide for obesity (Novo Nordisk, FDA 2021)

Tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid linker, molecular weight 4813.45 Da. Semaglutide is a 31-amino-acid GLP-1 analog with a C18 fatty diacid linker, molecular weight 4113.58 Da. Both are once-weekly injectable peptides with multi-day half-lives (tirzepatide approximately 117 hours, semaglutide approximately 165 hours). The 700-Da molecular weight difference reflects tirzepatide eight extra residues plus a different fatty acid spacer.

Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a unimolecular dual agonist of GLP-1 and GIP receptors. GIP, glucose-dependent insulinotropic polypeptide, contributes additional insulinotropic and lipid-handling effects. The dual mechanism is the leading hypothesis for tirzepatide superior weight-loss efficacy seen in head-to-head and cross-trial comparisons, although the relative contribution of GIP agonism versus GLP-1 receptor pharmacology remains an active research question.

SURMOUNT-5 was the direct head-to-head trial comparing tirzepatide and semaglutide for chronic weight management without T2D. Reported topline results showed mean percent change in body weight at 72 weeks of approximately -20.2% with tirzepatide at maximum tolerated dose versus -13.7% with semaglutide 2.4 mg. The absolute difference of approximately 6.5 percentage points is the largest within-class differentiation reported between two approved injectable peptide weight-loss agents to date.

In type 2 diabetes, SURPASS-2 directly compared tirzepatide 5/10/15 mg with semaglutide 1.0 mg over 40 weeks. HbA1c reductions were approximately -2.0%, -2.2%, and -2.3% for tirzepatide doses versus -1.9% for semaglutide. Body weight reductions were -7.6, -9.3, and -11.2 kg for tirzepatide versus -5.7 kg for semaglutide. Tirzepatide showed dose-dependent superiority on both glycemic and weight endpoints, with a tolerability profile comparable to semaglutide at the lower tirzepatide doses.

Both compounds use stepwise dose titration to manage gastrointestinal tolerability. Tirzepatide for obesity titrates 2.5, 5, 7.5, 10, 12.5, 15 mg weekly with target maintenance at 10-15 mg. Semaglutide for obesity titrates 0.25, 0.5, 1.0, 1.7, 2.4 mg weekly with target maintenance at 2.4 mg. The diabetes versions cap at 15 mg (Mounjaro) and 2.0 mg (Ozempic) respectively.

Both compounds share a class adverse event profile dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation. Rates are largely concentrated during titration and decline at maintenance dosing. Pancreatitis, gallbladder events, and acute kidney injury appear at low rates in both. Thyroid C-cell tumors carry a boxed warning for both based on rodent data. Tirzepatide shows slightly higher GI event rates at the highest doses, consistent with its greater pharmacological potency.

• Nausea: tirzepatide 25-33%, semaglutide 24-44% (varies by trial)
• Diarrhea: tirzepatide 19-23%, semaglutide 22-30%
• Discontinuation for AEs: tirzepatide 4-7%, semaglutide 4-7%
• Pancreatitis: <0.5% both
• Gallbladder events: 1-2% both

The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. Both products now operate in normal supply. U.S. list prices in 2026 are approximately $1,069 for Mounjaro/Zepbound and $968-$1,349 for Ozempic/Wegovy. Insurance coverage continues to favor T2D indications, while obesity coverage expansions linked to cardiovascular outcomes data are reshaping access in 2026.

For research professionals comparing the two molecules, the relevant axes are receptor pharmacology (GIP/GLP-1 dual vs GLP-1 single), per-mole potency, head-to-head efficacy data, and safety surveillance datasets. Cross-trial comparisons must control for population, baseline BMI, and dose. Both compounds are still accumulating long-term cardiovascular and renal outcome data in 2026, and several non-obesity indications are in late-stage trials.

Is tirzepatide stronger than semaglutide? In head-to-head trials it produces larger mean weight loss and similar or greater HbA1c reduction at FDA-approved maximum doses. Are Mounjaro and Zepbound the same? Yes, both are tirzepatide, differing only in indication and dose pen labeling. Will research-grade tirzepatide replicate clinical results? It is the same molecule, but research-grade material is not formulated, sterile, or labeled for human use and is intended only for laboratory study.

• Read more: Ozempic vs Wegovy: Same Drug, Different Indications Explained 2026 → https://www.chemverify.com/learn/ozempic-vs-wegovy-same-drug-different-2026
• Read more: Best Peptides for Fat Loss 2026: Evidence-Based Rankings → https://www.chemverify.com/learn/best-peptides-for-fat-loss-2026-evidence-rankings
• Read more: Tirzepatide vs Semaglutide 2026: SURMOUNT-5 Head-to-Head Results Compared → https://www.chemverify.com/learn/semaglutide-vs-tirzepatide
• Read more: Ozempic Alternatives: 7 Verified Research Peptides Compared 2026 → https://www.chemverify.com/learn/ozempic-alternatives-7-verified-peptides-2026